Partial
Partially Aligned
Patient Risk:
Medium
Summary
Several prescribing-information elements (indications, fibromyalgia, some seizure indication scope, and specific warnings like dizziness/somnolence and weight gain) are supported, but many other claims are not supported by the provided label text (notably patents/legal/pricing/insurance and several safety/mechanism details). Additionally, the set of included claims omits multiple material safety sections (e.g., boxed warning/contraindications and pregnancy/renal impairment elements) from the provided coverage, resulting in only partial label alignment.
Category Scores
Accurate Statements
Lyrica is prescribed to treat neuropathic pain.
Supported by Indications and Usage (1).
Neuropathic pain treated with Lyrica can be associated with diabetic peripheral neuropathy.
Supported by Indications and Usage (1).
Neuropathic pain treated with Lyrica can be associated with postherpetic neuralgia.
Supported by Indications and Usage (1).
Lyrica is used for fibromyalgia.
Supported by Indications and Usage (1).
Lyrica is used as an add-on treatment for partial-onset seizures in adults.
Supported by Indications and Usage (1) and Adjunctive therapy for partial-onset seizures in patients 1 month of age and older (2.4), though the claim is narrower than label scope.
Lyrica By modulating these signals, Lyrica helps to alleviate pain.
Supported by Mechanism of Action (12.1) and/or Indications and Usage (1).
Lyrica helps to control seizures.
Supported by Indications and Usage (1) and/or Mechanism of Action (12.1).
Common side effects of Lyrica can include dizziness.
Supported by Warnings and Precautions (5.5 Dizziness and Somnolence).
Common side effects of Lyrica can include drowsiness.
Supported by Warnings and Precautions (5.5 Dizziness and Somnolence).
Common side effects of Lyrica can include weight gain.
Supported by Warnings and Precautions (5.8 Weight Gain).
Standard dosages for Lyrica are determined by the condition being treated.
Supported by the dosage sections for multiple indications (2.2, 2.3, 2.4, 2.5) and Indications and Usage (1).
Dosage adjustments for Lyrica are made based on individual patient response and tolerance.
Supported by dosage sections where dose may be increased based on efficacy and tolerability (2.2, 2.3, 2.4).
Pregabalin (Lyrica) is chemically related to gabapentin.
Supported by Mechanism of Action (12.1) stating structural relation to compounds such as gabapentin.
Unsupported Statements
Lyrica has been subject to patent protection.
Not supported by the provided FDA label sections.
Legal challenges to Lyrica patents have occurred, including attempts by companies to invalidate patents to allow generic entry.
Not supported by the provided FDA label sections.
Patent expiration is a key factor in the introduction of generic versions of the drug.
Not supported by the provided FDA label sections.
Following patent expirations, generic versions of pregabalin have become available.
Not supported by the provided FDA label sections.
Generic pregabalin typically offers a lower price point compared to branded Lyrica.
Not supported by the provided FDA label sections.
The cost of Lyrica can vary depending on the dosage and formulation.
Not supported by the provided FDA label sections.
The cost of Lyrica can vary depending on whether a generic alternative is available.
Not supported by the provided FDA label sections.
Insurance coverage plays a significant role in out-of-pocket expenses for patients taking Lyrica.
Not supported by the provided FDA label sections.
Common side effects of Lyrica can include dry mouth.
Dry mouth is not supported by the provided label text excerpts.
Lyrica dosage is prescribed by a healthcare professional.
Not supported by the provided FDA label sections.
Gabapentin is used to treat neuropathic pain and seizures.
Not supported by the provided FDA label sections.
Differences in pharmacokinetics and clinical efficacy between pregabalin and gabapentin may influence prescribing decisions.
Not supported by the provided FDA label sections.
Contradictions
Low
AI Statement
Lyrica is used as an add-on treatment for partial-onset seizures in adults.
Label Reference
Indications and Usage (1) and Adjunctive therapy for partial-onset seizures in patients 1 month of age and older (2.4) specify patients 1 month of age and older, not adults only.
Important Omissions
Boxed warning / major contraindications content is not addressed in the provided claims set.
Importance:
High
Pregnancy / fertility / lactation risk communication is not represented in the provided claims set.
Importance:
High
Renal impairment dosing/safety specifics (and related monitoring) are not represented; the claims only mention dose adjustment based on response/tolerance.
Importance:
High
Other serious warnings listed in the provided labeling (e.g., hypersensitivity, suicidal behavior/ideation, respiratory depression, peripheral edema, tumorigenic potential, ophthalmological effects, etc.) are not captured by the provided claims set.
Importance:
Moderate
Pediatric scope (1 month of age and older for seizure indication) is not reflected in the provided seizure claim wording (it states adults only).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
While some supported adverse effects are mentioned (dizziness/somnolence and weight gain), multiple material safety elements (e.g., contraindications/boxed warning content, pregnancy risk, and renal impairment dosing/safety) are omitted from the evaluated set of claims, which could reduce label-aligned safe-use communication.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Many claims are absent from the provided labeling excerpts (patents/legal/pricing/insurance; dry mouth; healthcare-professional prescription statement; gabapentin use and PK/efficacy comparisons). Major safety sections (boxed warning/contraindications, pregnancy, renal impairment dosing/safety, and other listed serious warnings) are not represented.
Suggested Improvement
Restrict claims to the provided label sections: cover only labeled indications, dosing framework, and label-supported adverse reactions/warnings; remove non-label content (patents/legal/price/insurance). If discussing seizures, include label scope (patients 1 month of age and older). Add label-cited safety essentials (contraindications/boxed warning if present in the full label, pregnancy risk, and renal impairment dosing guidance).